Overview of Lertus Forte

Lertus Forte is a specialized medication classified as a fixed-dose combination analgesic, formulated into an oral tablet for patients requiring comprehensive management of intense pain involving an inflammatory component. The product's identity is defined by its strategic blend of two distinct active ingredients.

Quick Facts	Description
Active Ingredients	Codeine and Diclofenac
Form	Oral Tablet (Comprimido)
Pharmacological Class	Combination Analgesic (Opioid Agonist + NSAID)
Common Use	Relief of intense pain with an inflammatory component
Origin	Synthetic (Diclofenac) and Semi-synthetic (Codeine)

What Type of Medicine is Lertus Forte?

Lertus Forte is a combination product that belongs to two major pharmacological classes: Opioid Analgesics and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This dual classification means the medication intervenes on pain using both central and peripheral mechanisms. The tablet dosage form is intended for oral administration, a common route for achieving systemic analgesic effects. The active ingredient Diclofenac is globally recognized as an established NSAID for its potent anti-inflammatory action, which correlates with its role in reducing inflammation and associated discomfort.

Composition: The Dual-Action Active Ingredients

The formulation features two active substances: Codeine and Diclofenac. Diclofenac is a completely synthetic compound classified as a phenylacetic acid derivative, while Codeine is a semi-synthetic derivative that originates from natural opium alkaloids. Lertus Forte typically uses specific salts such as Diclofenac sodium and Codeine phosphate hemihydrate. Codeine is a centrally acting opioid which functions by binding to mu-opioid receptors to alter the perception of pain. This indicates that the Codeine component works directly on the central nervous system to reduce the feeling of pain.

General Purpose: Synergy for Intense Pain Relief

The core purpose of Lertus Forte is to deliver powerful, combined relief for intense pain that benefits from simultaneous anti-inflammatory action, such as pain related to musculoskeletal discomfort. The clinical strategy behind combining these two ingredients relies on a synergistic effect. The central effect of Codeine works by increasing the pain tolerance threshold, while the peripheral effect of Diclofenac directly reduces inflammation and swelling at the source by inhibiting prostaglandin synthesis. This combined action is designed to provide greater overall therapeutic benefit than either component could achieve individually, making Lertus Forte a robust choice for managing significant discomfort.

Regulatory References

National Library of Medicine - NIH

What side effects are possible with Lertus Forte?

Lertus Forte: Possible Side Effects and Safety Information

Lertus Forte, which contains an active Nonsteroidal Anti-inflammatory Drug (NSAID) component, carries significant safety warnings concerning serious adverse reactions affecting multiple body systems, particularly the cardiovascular and gastrointestinal systems.

Serious and Clinically Significant Adverse Reactions

Regulatory authorities mandate a Boxed Warning to highlight the following potentially fatal risks:

Cardiovascular Thrombotic Events: Use, especially long-term or at high doses, may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction (MI) and stroke. This risk can occur early in treatment.
Gastrointestinal (GI) Events: NSAIDs increase the risk of GI bleeding, ulceration, and perforation of the stomach or intestines, which may be fatal. These serious events can occur without warning symptoms.

Additional serious adverse events include nephrotoxicity (kidney damage/failure), hepatotoxicity (liver damage/failure), and severe skin reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis).

Common Adverse Reactions

The most commonly reported side effects typically involve the gastrointestinal system (e.g., indigestion, nausea, vomiting, stomach pain, constipation, diarrhea) and the nervous system (e.g., headache, dizziness, drowsiness).

Safety Restrictions and Population-Specific Considerations

Contraindications: Lertus Forte is contraindicated for the treatment of pain immediately before or after Coronary Artery Bypass Graft (CABG) surgery. It is also contraindicated in patients with a history of asthma, hives (urticaria), or allergic-type reactions after taking aspirin or other NSAIDs.
Elderly Patients: Older adults are at a greater risk for serious GI events and should use the lowest effective dose for the shortest duration possible.
Dose/Exposure Pattern: The risks of serious cardiovascular and gastrointestinal events are generally considered to be dose- and duration-dependent, meaning risk increases with higher doses and longer periods of use.

Overdose and Emergency Response

The official regulatory profile for Lertus Forte overdose addresses the distinct toxicological risks of both Codeine and Diclofenac. Overdose manifestations related to the opioid component include slow, shallow, or irregular breathing, profound sedation, dizziness, confusion, or progression to unresponsiveness. The skin may appear pale or bluish (cyanosis) due to this respiratory depression, which can be a fatal outcome.

Manifestations from the NSAID component (Diclofenac) include nausea, vomiting, stomach pain, or diarrhea, with severe cases potentially leading to internal gastrointestinal bleeding or acute renal failure. Both components carry a risk of severe or life-threatening outcomes.

Immediate emergency medical attention is mandated upon suspected overdose or accidental ingestion. Urgent help is required if a person exhibits severe symptoms such as difficulty breathing, seizures, or inability to respond. Overdose management is primarily symptomatic and supportive. Naloxone is available for the reversal of Codeine-induced respiratory depression. No specific antidote is documented for the Diclofenac component.

Specific population-based risks are noted: the Codeine component is contraindicated in children under 12 years of age and in individuals who are ultra-rapid metabolizers due to a documented heightened risk of life-threatening respiratory depression.

Therapeutic Uses of Lertus Forte

What Lertus Forte Treats: Main Uses and Benefits

The primary therapeutic role of Lertus Forte is to support symptomatic relief through a dual therapeutic approach, addressing intense pain associated with symptoms related to inflammatory or irritative states. A core component of this medication is used within therapeutic areas involving heightened responses, relevant for easing pain and inflammation in a wide range of conditions.

Lertus Forte is commonly used across conditions characterized by episodic or acute symptom patterns where the level of discomfort creates noticeable interference with daily stability. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as contexts involving heightened systemic burden, and is applied in conditions marked by heightened symptoms, including acute flare-ups of inflammatory arthritis and severe sciatica. The medication helps address groups of symptoms that may become intense or disruptive, such as those related to physical discomfort in nerve pathways.

This provides support that helps ease the overall symptom burden, and may assist with maintaining functional stability during difficult symptomatic periods.

Quick Fact: Relief for Intense Inflammatory Pain
Main Symptom Target	Intense pain and symptoms related to inflammatory or irritative states
Common Use Context	Acute episodes, post-trauma, or inflammatory flare-ups
Patient Benefit	Assists with maintaining functional stability and supports general well-being

Eligibility and Restrictions for Use

The eligibility for Lertus Forte (Codeine/Diclofenac) is strictly governed by regulatory rules regarding age, genetic status, and pre-existing medical conditions.

Populations for Whom Use is Contraindicated

Category	Non-Eligibility Status
Age Restriction	Children under 12 years of age [Source 2.1].
Genetic/Metabolic	Patients known to be CYP2D6 ultra-rapid metabolizers [Source 2.3].
Reproductive Status	Breastfeeding mothers and women in the third trimester of pregnancy [Source 2.3, 1.5].
Severe Organ Failure	Patients with severe hepatic or renal failure [Source 1.1].
Gastrointestinal Health	Patients with active gastrointestinal ulceration, bleeding, or a history of recurrent ulceration [Source 1.3].
Cardiovascular Status	Patients with established congestive heart failure (NYHA Class II-IV) or following Coronary Artery Bypass Graft (CABG) surgery [Source 3.2, 1.5].

Age-Related and Conditional Restrictions

Adolescents (lt 18 years): The medicine is contraindicated following tonsillectomy and/or adenoidectomy for obstructive sleep apnea [Source 2.3].
Older Adults: Use requires caution due to increased susceptibility to gastrointestinal and cardiovascular adverse events [Source 1.2].
Mild Impairment: Patients with mild to moderate renal or hepatic impairment should be monitored closely [Source 1.4].

Regulatory documents define eligibility based on cumulative risks from both Codeine and Diclofenac, with absolute contraindications established for vulnerable groups and pre-existing severe conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lertus Forte’s interaction profile is defined by the regulatory constraints associated with its dual components: Codeine and Diclofenac. Formal restrictions classify combinations with Monoamine Oxidase Inhibitors (MAOIs) as contraindicated; a washout period of at least 14 days is required after discontinuing an MAOI. Co-administration with other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is also prohibited due to the risk of additive gastrointestinal and systemic undesirable effects.

Significant pharmacodynamic interactions exist with Central Nervous System (CNS) depressants, including benzodiazepines and alcohol, which may lead to profound sedation and respiratory depression. The Diclofenac component requires caution when co-administered with anticoagulants or antiplatelet agents, as this increases the documented risk of serious bleeding events. Additionally, the efficacy of ACE inhibitors and diuretics may be diminished by Diclofenac, which also reduces the renal clearance of drugs like Lithium and Digoxin, increasing their serum concentrations.

Metabolic interactions are documented via the Cytochrome P450 (CYP) enzyme system. Inhibition of CYP2D6 may reduce the formation of codeine’s active metabolite, which can compromise analgesic efficacy. Conversely, CYP2C9 inhibitors increase the plasma concentration of Diclofenac. Finally, individuals who are CYP2D6 ultra-rapid metabolizers have a specific population-based caution due to the risk of high, rapid conversion to morphine.

Mechanism of Action

Dual Modulation: Targeting Enzymes and Central Receptors

The drug's action is defined by a dual mechanism, engaging two separate pharmacological systems to influence multiple pathways. One component acts as an enzyme inhibitor to suppress the activity of Cyclooxygenase (COX) enzymes in peripheral tissues. The other component functions as a receptor agonist on Mu-opioid receptors (mu-receptors), primarily within the central nervous system. This strategy directs the drug to influence both peripheral chemical mediators and central neural signaling.

Interference with Peripheral Inflammatory Signals

Inhibition of COX enzymes limits the synthesis of prostaglandins, which are key chemical mediators of inflammation. Modifying these early molecular steps influences downstream effects, resulting in decreased vasodilation and fluid extravasation at the affected site.

Action on Central Pain Transmission Pathways

The activation of mu-receptors in the brain and spinal cord modifies neuronal signaling, interfering with the flow of nociceptive impulses. This mechanism engages a central pathway that influences feedback regulation, resulting in decreased neuronal excitability and decreased nociceptive signal transmission in the central nervous system.

Dosage and Administration Information

How to Use Lertus Forte

Lertus Forte is administered as a fixed-dose oral tablet and is intended for use in an acute, short-term regimen. Standard guidelines govern the route of administration, maximum allowed doses, and the duration of the treatment course. This structure ensures adherence to the limits of both active components.

Official Administration Guidelines

Usage Parameter	Regulatory Instruction
Route of Administration	The tablet must be taken orally and swallowed whole with liquid; it must not be crushed or chewed.
Timing in Relation to Meals	It is generally advised to take the tablet with or immediately after food or milk to reduce potential gastrointestinal irritation associated with the Diclofenac component.
Frequency and Interval	Dosing is typically multiple times per day (in divided doses), with a minimum required interval of 4 to 6 hours between each dose.
Dose Limits	The total daily dose must not exceed the maximum allowed for either component, which is 150 mg for the Diclofenac component and generally 240 mg for the Codeine component

Duration and Specific Populations

Treatment must be time-limited, and the total duration for pain relief with Codeine-containing products should not exceed three days. If pain relief is not achieved within this short period, the patient should seek a physician's view. Dosing must be carefully adjusted for specific populations: the medicine is contraindicated in children under 12 years of age and requires the use of the lowest effective dose in older adult patients.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Lertus Forte

This overview summarizes the official research conducted on the fixed-dose combination of Diclofenac and Codeine, focusing on the types of clinical studies available and what scientists have explored. It is designed to provide context on the evidence base without offering medical advice or treatment instructions.

Evidence for Acute Pain and Inflammation

Research exploring this combination includes Randomized Controlled Trials (RCTs) and Systematic Reviews used in research exploring how symptoms change over time. These studies have focused on the combination in study settings involving acute, moderate to severe pain. Outcomes studied were related to physical discomfort. Studies reported various measurements of total pain score change recorded in the observed populations following treatment. Follow-up durations were limited, consequently, long-term outcomes and safety patterns are not well characterized beyond the short-term treatment period.

Evidence for Postoperative Pain Management

This evidence base is dominated by placebo-controlled RCTs, the design of which assesses short-term or episodic symptom patterns following procedures such as minor surgery. Study outcomes examined focused on physical discomfort, including the quantification of pain intensity and evaluation of functional disability markers. Findings describe patterns observed in the studies related to the time measured until a specified pain reduction endpoint and how long that effect lasted. Reported data largely addressed the single-dose evaluation of the combination, meaning research provides limited information for long-term outcomes.

Key Limitations and Areas of Uncertainty

Key limitations include the fact that follow-up durations were limited across the majority of efficacy trials, meaning that data are still emerging regarding long-term effects. The results apply only to the populations studied, and comparative evidence is lacking in several complex indications. Research is ongoing, and findings suggest patient response variability due to differences in Codeine metabolism, leading to variability in outcomes observed across study groups.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Lertus Forte (FAQ)

Q: Is Lertus Forte the same medicine as its generic name?

Lertus Forte is the brand name assigned to this specific combination medication. According to official product information, the generic names of the two active substances it contains are Codeine and Diclofenac.

Q: Does Lertus Forte treat the underlying cause of a condition or only the symptoms?

Official regulatory information indicates that Lertus Forte is intended for the relief of signs and symptoms, such as pain and inflammation. The mechanism of action is focused on influencing chemical pathways and central pain signals to provide symptomatic relief, not to cure the underlying condition.

Q: What are the typical pain conditions Lertus Forte is indicated to treat?

The official product information states this combination is indicated for managing acute, moderate to severe pain that benefits from both components. The Diclofenac part of the medicine is approved to help relieve symptoms of inflammatory conditions like osteoarthritis and rheumatoid arthritis.

Q: Are there any common over-the-counter pain relievers that should be avoided when taking Lertus Forte?

According to the official product label, co-administration with other systemic NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) is generally avoided. This includes common over-the-counter pain relievers like ibuprofen or naproxen, as taking them together increases the risk of combined adverse effects.

Q: What are the signs of a serious allergic reaction to Lertus Forte?

Signs of a serious allergic reaction, known as anaphylaxis, can include sudden symptoms like difficulty breathing, the development of hives or a rash, or swelling of the face or throat. Official warnings also highlight the risk of very serious skin reactions, such as Stevens-Johnson syndrome, which require immediate medical attention.

Q: Are there any foods or beverages that are known to interact with Lertus Forte?

Official product information specifically warns that alcohol should be avoided, as combining it with Lertus Forte can increase the risk of side effects like heavy sedation, breathing issues, and gastrointestinal bleeding. No common food or non-alcoholic beverage interactions are explicitly noted in the regulatory documents for this combination.

Q: Does Lertus Forte have any warnings about sun sensitivity or skin rash?

Official regulatory warnings for the Diclofenac component list reports of photosensitivity, which means an increased sensitivity to sunlight. Additionally, official guidance states that the drug should be discontinued at the first sign of a skin rash.

Q: What should be done if a user experiences unexpected bruising while taking Lertus Forte?

Official documentation indicates a general risk of bleeding events for this medication. Experiencing symptoms like unexpected bruising (ecchymosis) or skin hemorrhages are listed as possible adverse reactions. If a user notices symptoms such as unexpected bruising, regulatory documents indicate this should be discussed with a healthcare professional.

Q: Can Lertus Forte affect a person's ability to drive or operate machinery?

Yes, according to the official product information. Because side effects like dizziness and drowsiness are common, regulatory guidance cautions patients against driving or operating dangerous machinery until they are aware of how the medication affects them.

Q: Why is Lertus Forte sometimes prescribed with a stomach-protecting medication?

Regulatory labeling mandates a Boxed Warning highlighting the risk of gastrointestinal bleeding, ulceration, and perforation due to the NSAID component (Diclofenac). Stomach-protecting agents are often prescribed alongside Lertus Forte to help mitigate this serious and documented risk.

Q: Is it normal to feel tired or fatigued when taking Lertus Forte?

Official information lists drowsiness as a common side effect of the medication. Additionally, in clinical studies for the Codeine component, the broader feeling of fatigue has been reported as an adverse event.

Q: What are the potential signs of a serious side effect on the kidneys from Lertus Forte?

The drug is associated with a risk of nephrotoxicity, which is damage to the kidneys. The official label notes that signs of potential kidney issues can include fluid retention or swelling (edema), a decrease in the amount of urine produced, or sudden changes in blood pressure.

Q: Can people with high blood pressure take Lertus Forte?

Official regulatory warnings state that the Diclofenac component should be used with caution in people with hypertension (high blood pressure). Furthermore, official labeling includes a statement that blood pressure is generally monitored closely when starting treatment and throughout therapy.

Q: What is the standard onset time for Lertus Forte to begin providing pain relief?

Based on the pharmacokinetics of the Codeine component, the drug typically begins its onset of action between 15 and 30 minutes after ingestion. The maximum analgesic effect usually occurs within two hours.

Q: How long is a single dose of Lertus Forte expected to last?

Official product information indicates that the analgesic effect provided by the Codeine component typically lasts for 4 to 6 hours. This duration corresponds to the minimum required interval between doses for this medication.

Q: Is there a possibility of Lertus Forte causing fluid retention or swelling (edema)?

Yes, according to regulatory warnings for the Diclofenac component. The label states that fluid retention (edema) and the onset or worsening of heart failure have been reported with the use of NSAIDs.

Q: Have there been studies conducted on Lertus Forte's use in pediatric patients?

Official regulatory labeling states that the safety and efficacy have not been established in pediatric patients under 12 years of age. Furthermore, the drug is officially contraindicated in this age group due to safety concerns.

Q: Does Lertus Forte carry a risk of physical dependence or addiction?

Yes. Since Lertus Forte contains Codeine, which is classified as an opioid, the official label includes warnings about the risk of addiction, abuse, and misuse. These risks exist even when the medication is taken as prescribed and not misused.

Q: Can Lertus Forte cause ringing in the ears (tinnitus)?

According to official product labeling, ringing in the ears (tinnitus) is listed as a possible adverse effect related to the Diclofenac component of this medication.

Q: Can Lertus Forte be used for pain related to menstrual cramps?

The Diclofenac component of the medication is officially indicated for the treatment of pain and inflammation. While the combination product may not explicitly list it, the Diclofenac component’s action is suitable for conditions like menstrual cramps (dysmenorrhea) under its general pain-relief indication.

Q: Can the effectiveness of Lertus Forte decrease over time with continued use?

The official label for the Codeine component includes warnings about the potential for tolerance with repeated use. Tolerance means that a person may experience a decreased response to the same dose of the drug over time.

Q: Can Lertus Forte interfere with the effectiveness of birth control pills?

Studies have linked Diclofenac, the NSAID component, to a small increased risk of blood clots (venous thromboembolism or VTE) when used alongside hormonal contraceptives. While not a direct interference with efficacy, official advice highlights the need for patients to be aware of this potential risk.

Q: Is Lertus Forte used to treat conditions other than inflammation and pain?

While its primary purpose is pain and inflammation relief, the Diclofenac component of the medicine also has anti-pyretic action. This means it may also be used for reducing fever, a common use for NSAID-class medications.

Q: Is Lertus Forte a treatment for migraines or other types of headaches?

Yes, specific formulations of the Diclofenac component are officially indicated for the treatment of acute migraine headaches. This use is based on the drug’s anti-inflammatory and pain-relief properties.

Q: Is Lertus Forte considered a narcotic or opioid medication?

Yes, Lertus Forte contains Codeine, which is classified as an opioid analgesic. Because of this, it is regulated as a controlled substance due to the official warnings regarding the risks of abuse and dependence.

How should Lertus Forte be stored and disposed of?

How to Store and Dispose of Lertus Forte

Lertus Forte (Codeine and Diclofenac) must be stored under specific environmental constraints to maintain the stability of its active ingredients, as mandated by regulatory documents.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C, not exceeding 30 C.
Protection	The medicine must be protected from light and moisture and should not be frozen.
Container	Keep the tablets in their tightly closed, original container.
Child Safety	Keep out of the sight and reach of children and pets at all times.

Disposal Instructions

Unused or expired Lertus Forte must be handled as pharmaceutical waste. Disposal should be carried out in accordance with local regulatory requirements, such as utilizing an official drug take-back program. The medicine must not be flushed down the toilet or disposed of in household wastewater.

Lertus Forte